Indeed, recent findings suggest that IDO1 in tumor cells and non-tumor cells possess different functions that are non-overlapping, which may have bearing on difference in targetability with first generation of IDO1 inhibitors primarily focused on catalytic activity (124, 125). Here, IDO1 is linked to neoplasm.